Enable Injections announced a Bluetooth-enabled version of its Enable Wearable Injector that allows patients to easily self-administer large volume drugs subcutaneously, while also enabling compliance monitoring and big data capture with a mobile app.

Said device has a small profile, making it easier to infuse/inject a drug while on-the-go. Also, the Wearable Injector will adapt to each user, while providing him/her with tactile feedback at the end of dose. This, the company claims, ensures minimum administration time and minimal device preparation.

Beyond mobile connectivity, Enable Injections also announced market leading volume capabilities — the Enable Injector can now comfortably deliver up to 50 mL doses of high volume and/or viscous biologics subcutaneously.

“The benefit for Bio-Pharma companies is they can get their product into clinical evaluation quicker as there is no need to spend time on additional formulation to achieve low volumes,” said Enable Injections CEO Michael D. Hooven. “In addition, now pharmaceutical companies, physicians and patients can each have the tracking data they need by using a mobile app or Bluetooth connected device. The ultimate goal is that the new drug delivery technology will not only benefit patients by improving their health outcomes, but also lower costs by streamlining drug development and replacing costly hospital-based infusions.”